Life Science Partner recruits former VP of Finance & Administration and Principal Accounting Officer of AtheroGenics, Inc.
Life Science Partner announces the recruitment of Charles Deignan, an experienced pharmaceutical finance executive, to Metastatix, Inc. Metastatix is an emerging pharmaceutical company developing and commercializing effective, convenient and safe small-molecule drugs for a broad portfolio of indications including cancer, HIV infection and inflammation. The company’s initial focus has been on the CXCR4 receptor, a critical mediator of cellular and chemical trafficking.
Deignan was most recently Vice President of Finance & Administration and Principal Accounting Officer for AtheroGenics, Inc., an emerging pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceutical products for the treatment of chronic inflammatory diseases. In this role, he was responsible for all areas of finance and accounting, as well as risk management, information systems and human resources for the company. Previously, Deignan was Division Controller for AAI Pharma, Inc. in Wilmington, North Carolina where, among other financial responsibilities, he directed the financial reporting related to the company’s IPO.
“Deignan is a proven, roll-up-your-sleeves financial executive who understands the challenges of an early-stage company,” noted Tom Callaway, MD, founder and president of Life Science Partner. “In addition, he brings many other skill sets to the company with his demonstrated experience in human resources, information technology and clinical trials contracting and management.”
Metastatix recently raised a $35M Series B round from a nationally recognized group of venture investors including Frazier Healthcare Ventures, HIG Ventures, SROne, Aruna, and Georgia Venture Partners.
Deignan earned his Bachelor of Science degree in Business Administration from Boston University’s School of Management and is a Certified Managerial Accountant.